- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Strengths and Limitations of Current Therapeutic Options
Panelists discuss how treatment individualization depends on patient-specific factors including age, comorbidities, disease severity, and personal preferences, balancing clinical guidelines with shared decision-making to optimize both efficacy and adherence.
EP: 1.Pathophysiology of Pulmonary Arterial Hypertension
EP: 2.Differential Diagnosis of Pulmonary Arterial Hypertension
EP: 3.Importance of Early Detection and Monitoring for Disease Progression
EP: 4.Risk Stratification and the Importance of Patient-Centered Care
EP: 5.Strengths and Limitations of Current Therapeutic Options
EP: 6.Overview of Different Therapies for Patients with Pulmonary Arterial Hypertension
EP: 7.Sotatercept for Patients with Pulmonary Arterial Hypertension
EP: 8. The Role of the Prostacyclin Pathway
EP: 9.Important Clinical Considerations for Pulmonary Arterial Hypertension
EP: 10.Economic Impact of Pulmonary Arterial Hypertension
EP: 11.Barriers to Care for Patients with Pulmonary Arterial Hypertension
EP: 12.Utilizing Health Economic Outcomes in Clinical Practice
EP: 13.Outlining the Need for Equitable Access to Care
EP: 14.Final Panelist Thoughts on the Management of Pulmonary Arterial Hypertension
Current Therapeutic Landscape and Limitations
The current pulmonary arterial hypertension therapeutic arsenal includes approximately 15 approved treatments in the United States, representing a dramatic evolution from the single-therapy era of 2 decades ago. These medications target different pathways including endothelin receptor antagonism, nitric oxide-cGMP signaling, prostacyclin pathways, and the newer activin signaling inhibition. The diversity of available treatments enables individualized therapy selection and combination approaches that can provide synergistic benefits.
Despite therapeutic advances, significant limitations persist in current treatment options, particularly regarding delivery methods, adverse effect profiles, and complexity of administration. Treatment options range from simple once-daily oral medications to complex 24-hour continuous infusions requiring specialized monitoring and administration. Unfortunately, health care inequities and access limitations sometimes result in patients receiving simpler but potentially less appropriate therapies rather than optimal treatment regimens.
The field has addressed some therapeutic limitations through aggressive upfront combination therapy, typically initiating at least 2 medications simultaneously and sometimes 3 drugs in severely ill patients. This approach maximizes the probability of targeting effective pathways in individual patients while overcoming the limitation of not having precision medicine approaches. Aggressive monitoring and therapy escalation strategies further help ensure that patients receive effective treatment regimens despite inherent therapeutic challenges.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
